Platelet Reactivity in Acute Non-disabling Cerebrovascular Events "PRINCE"

Recruiting

Phase 2/3 Results N/A

Summary of Purpose

Ticagrelor is a reversible and direct-acting oral antagonist of the P2Y12 (Purinergic receptor P2Y, G-protein coupled, 12) receptor for adenosine diphosphate, which provides faster, greater, and more consistent P2Y12 inhibition than Clopidogrel in patients with acute coronary syndrome, irrespective of the genetic variants affecting Clopidogrel metabolism. It is still undefined whether combination therapy of...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 17 May 2016.

1 Aug 2015 19 Jul 2015 1 Jul 2016 1 Oct 2016 1 May 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind (Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Efficacy Study
  • Intervention: Parallel Assignment

Contacts